JNJQ3 20261/5Estimate vs Actual
Earnings per Share
- Estimate
- $2.56
- Actual
- $2.59
+1.0% vs Estimate
Revenue
- Estimate
- $25.5 B
- Actual
- $25.4 B
−0.5% vs Estimate
Johnson & Johnson Q3 2026 · Story
Read the quarter card by card, ready to share.
JNJQ3 20261/5JNJQ3 20262/5Guidance
Full-Year Reported Sales
- Company Guidance
- 101.0 – 101.4 B
- Market Estimate
- 101.4 B
In Line ✓ · 0.2% Below Expectation
Full-Year Adjusted EPS
- Company Guidance
- 11.05 – 11.15 $
- Market Estimate
- 11.08 $
0.2% Above Expectation ▲ · In Line
Full-Year Operational Sales Growth
- Company Guidance
- 6.7% – 7.1%
Midpoint Up 0.1 Point ▲
JNJQ3 20263/5Price Reaction
First Full Session
− 5.7%
From the prior close to the report-day close.
JNJQ3 20264/5In 30 Seconds
Sales of $25.4B beat expectations by 0.1% and adjusted EPS of $2.59 by 2.4%; GAAP EPS fell to $0.09 on the talc charge.
- Full-year adjusted EPS guidance rose to $11.05-$11.15; the midpoint is only 0.2% above the $11.08 expectation.
- The stock closed down 5.7% at $248.61 as MedTech sales missed the $8.71B expectation and overshadowed pharma strength.
First point of the analysis's “In 30 Seconds”.
Full AnalysisJNJQ3 20265/5Score
56/ 100
ViewHOLD
Not Investment Advice